NEW YORK – The US Food and Drug Administration on Thursday approved Pfizer's crizotinib (Xalkori) for pediatric patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) that is ALK-positive.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.